A shareholder letter caught the interest of investors. The letter being sent to shareholders details a special meeting taking place on March 15. The head of the letter notes that the meeting is for a proposed merger vote that will affect shareholders’ investment in the company.
Anchiano Therapeutics announced back in December plans to merge with Chemomab. The merger will have the management team of the combined company mostly made up of leaders from Chemomab. However, ANCN CEO Neil Cohen will serve on its Board of Directors.
It’s also worth pointing out that Anchiano Therapeutics started clinical trials for one of its treatments last month. This has it working to treat liver, skin, and lung fibrosis-related diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.